Off-Label Aesthetic Injections — What Patients and Providers Need to Understand

If you have received Botox in your masseter muscles for facial slimming, dermal filler in your temples for volume restoration, or Sculptra anywhere other than the nasolabial folds, you have received an off-label treatment. By some estimates, 20–60% of all drug and device use across medicine occurs off-label. In aesthetic medicine, that percentage may be even higher.

Off-label use is legal, common, and — when done thoughtfully by qualified providers — clinically appropriate. But "legal" and "common" are not the same as "risk-free" or "FDA-reviewed." Understanding the distinction matters for every patient who receives injectables and every provider who administers them.

What "Off-Label" Actually Means

The FDA approves drugs and clears devices for specific indications — specific conditions, specific anatomical areas, specific patient populations, and specific dosing parameters — based on the clinical evidence the manufacturer submitted during the approval or clearance process.

Off-label use occurs when a legally approved or cleared product is used in a way not specified on its label. This can include:

• A different anatomical area than the approved indication (e.g., injecting a filler approved for nasolabial folds into the nose or jawline)
• A different patient population than studied in the approval trials
• A different dosage or technique than specified in the label
• A different indication altogether (e.g., using a cosmetic injectable for a therapeutic purpose not studied in trials)

Crucially, off-label use is not illegal. The FDA regulates how products are marketed — not every clinical decision an individual physician makes. Once a product is approved, physicians may use it off-label within their scope of practice and state law, exercising clinical judgment.

Common Off-Label Uses in Aesthetic Medicine

Some of the most widely performed aesthetic injections are off-label:

Neuromodulators (Botox, Dysport, Xeomin, Daxxify, Jeuveau, Letybo)

Botox Cosmetic is FDA-approved for glabellar lines (frown lines), lateral canthal lines (crow's feet), forehead lines, and — as of October 2024 — platysma bands (vertical neck bands). Common off-label uses include:

• Masseter injection for facial slimming or bruxism (jaw clenching)
• Temporalis injection for facial slimming
• "TrapTox" (trapezius injection) for shoulder slimming
• Hyperhidrosis (excessive sweating) in areas beyond the underarms (the therapeutic Botox product is approved for axillary hyperhidrosis; other sites are off-label for the cosmetic product)
• Bunny lines, chin dimpling, and perioral lines
• Migraine prevention (therapeutic Botox is approved for chronic migraine; cosmetic formulations used for this purpose are off-label)

Dermal Fillers

The FDA has approved HA fillers for specific facial areas — primarily nasolabial folds, lips, cheeks, chin, and hands. As of 2024–2025, Juvéderm Voluma XC is also approved for temple injection, and SkinVive by Juvéderm has a supplemental application under FDA review for neck lines. Common off-label uses include:

• Non-surgical rhinoplasty (nose reshaping with filler) — the FDA explicitly notes that filler injection in the nose is not approved and carries heightened vascular risk
• Jawline contouring using fillers approved for other facial areas
• Tear trough injection — most fillers are not specifically approved for the under-eye area, where the anatomy presents elevated vascular occlusion risk
• Body contouring — the FDA recommends against using dermal fillers for breast or buttock augmentation
• Temple injection (before the 2024 Voluma approval for temples)

Biostimulators

Sculptra (PLLA) is FDA-approved for nasolabial fold correction. Radiesse (CaHA) is approved for nasolabial folds and hand volumization. Their use in other facial areas — jawline, temples, cheeks — is off-label, as is the diluted "bio-stimulatory" technique some providers use with Radiesse for skin quality improvement.

Why Off-Label Use Is Common

Off-label use is prevalent in aesthetic medicine for structural reasons:

The approval process is slow and expensive. Each new indication requires a separate FDA submission with supporting clinical data. For a manufacturer, the cost of running trials to expand a filler's label from "nasolabial folds" to "jawline contouring" may not justify the market return, especially when providers are already using the product for that purpose off-label.

Anatomy does not follow indication categories. A filler approved for nasolabial folds may have identical properties suitable for marionette lines or jawline definition. The product does not change — only the FDA-reviewed evidence base for that specific use.

Innovation outpaces regulation. Techniques like "Russian lips," the use of CaHA as a biostimulator rather than a volumizer, and combination protocols with PRP or exosomes evolve through clinical practice long before they reach FDA review.

Clinical evidence accumulates outside the label. Peer-reviewed literature, society guidelines, and expert consensus may support a use that the manufacturer has never formally submitted to the FDA.

What the FDA Does — and Does Not — Regulate

Understanding the boundaries of FDA authority is essential:

What the FDA regulates

• How products are marketed. Manufacturers cannot promote off-label uses in their advertising, sales materials, or representative communications. In January 2025, the FDA issued a Final Guidance describing certain types of manufacturer-initiated communications about off-label uses that should not trigger enforcement action — but the framework remains restrictive.
• What the product label says. The approved indication, contraindications, warnings, and dosing information on the label reflect what the FDA reviewed.
• Manufacturing and supply chain. Regardless of how a product is used, it must be manufactured according to FDA standards and distributed through authorized channels.

What the FDA does not regulate

• Individual physician prescribing decisions. Once a product is approved, a physician may use it off-label as a matter of clinical judgment. The FDA does not review or pre-approve individual treatment decisions.
• State scope-of-practice laws. Who can inject, under what supervision, and in what setting — these are state-level decisions. The FDA provides guidance but does not set these rules.
• Malpractice liability. If an off-label injection causes harm, the legal pathway is through medical malpractice and state licensing board action, not FDA enforcement against the provider.

Informed Consent Requirements for Off-Label Use

While off-label use is legal, the informed consent obligation is higher than for on-label treatments. Best practices — and increasingly, state board expectations — require that the provider:

1. Disclose that the use is off-label. The patient should understand that the FDA has not reviewed clinical data for this specific use. This does not mean the treatment is experimental — it means the regulatory pathway for this indication has not been completed.

2. Explain the evidence base. What is known about safety and efficacy for this off-label use? Is there peer-reviewed literature? Society guidelines? Extensive clinical experience? Or is the technique relatively novel with limited published data?

3. Discuss the specific risks. Off-label use may carry risks that differ from the on-label indication. Non-surgical rhinoplasty, for example, carries a higher vascular occlusion risk than nasolabial fold injection due to the anatomy of the nasal vasculature.

4. Document the conversation. The consent form should specifically reference the off-label nature of the treatment. Generic consent forms that do not mention off-label use may not provide adequate legal protection.

Several states have increased enforcement around informed consent in med spa settings. In New York, a December 2025 report from the City Council's Oversight and Investigations Division found violations at all 15 med spas inspected, with the first four completed cases resulting in license revocations. In January 2026, the New York Department of State cited 87 of 223 inspected businesses for potential violations, including unlawful practice of medicine. Rhode Island's Medical Spas Safety Act, signed into law June 30, 2025, requires that providers clearly explain risks, benefits, and alternatives and obtain written informed consent — with specific attention to whether treatments are off-label.

When Off-Label Crosses the Line

Not everything called "off-label" is a legitimate exercise of clinical judgment. Several categories of concern have emerged in 2024–2026:

Injecting products not approved for any aesthetic use

This is not off-label use — it is unapproved use. Examples include:

• Injecting PDGF (platelet-derived growth factor) products marketed as topical cosmetics. When a provider takes a cosmetic topical and injects it, the use is reclassified as drug or biologic administration, and the product has not been approved for injection. Regulatory and legal exposure is significant.
• Injecting compounded products that have not undergone FDA review. Compounded drugs are exempt from FDA approval requirements under certain conditions, but the compounding pharmacy must be licensed, and the formulation must be appropriate for the individual patient.
• Injecting products sourced from outside the US supply chain. Products purchased from overseas websites are not merely off-label — they may be counterfeit, adulterated, or improperly stored. This is a separate issue from clinical off-label use (see our guide on counterfeit injectable supply chain verification).

Marketing off-label use

While providers may use products off-label, they generally may not advertise off-label treatments in ways that imply FDA endorsement. Promotional materials stating that a filler "is FDA-approved for nose reshaping" when the approval is for nasolabial folds is misleading and can trigger FDA and FTC enforcement.

Delegation to unqualified providers

Off-label use is a medical decision that must be made by a qualified prescriber. A nurse injecting an off-label treatment without a physician's specific order — or a medical director who signs protocols without reviewing the off-label risk profile — creates liability for the practice. In states tightening med spa oversight, delegation of off-label treatments to unqualified staff is a common citation.

The Global Context

Off-label use in aesthetic medicine is not unique to the United States, but the regulatory framework varies significantly by country. In some markets, products approved for specific indications in the US or Europe may not yet be registered at all, creating a different set of regulatory and safety considerations.

For practices and manufacturers navigating cross-border product availability — particularly those evaluating aesthetic injectables or medical devices for markets where the regulatory framework differs from the US FDA model — the intersection of off-label clinical practice, import regulations, and local registration requirements creates complexity. Providers evaluating products manufactured or approved in other markets, including China's NMPA-registered aesthetic products, can find regulatory context at ChinaMedGlobal, which covers China medical device and pharma regulatory market access, including NMPA registration and market-entry strategy for medical products entering or leaving the Chinese market.

Risk Tiers for Common Off-Label Sites

Not all off-label use carries the same risk. The anatomical site, vascular supply, and available evidence base determine the risk profile:

Lower-risk off-label sites

These areas have substantial published experience, predictable anatomy, and well-characterized risk profiles:

• Masseter injection (Botox) — One of the most widely studied off-label uses. Extensive published data on dosing, outcomes, and safety. Main risks: temporary change in bite force, smile asymmetry if misplaced.
• DAO (depressor anguli oris) injection (Botox) — Small-dose injection to lift downturned mouth corners. Predictable anatomy, limited adverse event reports.
• Bunny lines (Botox) — Small-dose injection along the nasal sidewall. Low risk when placed correctly.
• Jawline contouring (HA filler) — Filler placed along the mandibular border using products approved for other facial areas. Moderate vascular risk in the pre-jowl sulcus region.

Higher-risk off-label sites

These areas require advanced anatomical knowledge, specific technique training, and more detailed informed consent:

• Nose (non-surgical rhinoplasty) — The FDA explicitly notes that filler injection in the nose is not approved. The nasal vasculature connects to the ophthalmic artery system, creating a documented risk of vascular occlusion and blindness. The Aesthetic Society's injectable safety workbook lists the nose as a high-risk zone.
• Tear troughs (under-eye) — Thin skin, superficial vasculature, and proximity to the eye make this area prone to visible product, Tyndall effect, and vascular complications. Only certain HA products are suitable, and even then, injection technique is critical.
• Temples — Before the 2024 Juvéderm Voluma XC approval for temple injection, all temple filler was off-label. The temporal region contains the superficial temporal artery; inadvertent intravascular injection can cause retinal artery occlusion.
• Forehead — Filler or neurotoxin placement in the forehead carries risk of vascular occlusion (filler) or brow/eyelid ptosis (neurotoxin), particularly near the supraorbital foramen.

Red-flag off-label use

These categories carry elevated risk and in some cases fall outside legitimate off-label practice entirely:

• Buttock or breast augmentation with HA filler — The FDA recommends against this practice. Volume requirements make it impractical, and the risk of vascular complications in large tissue planes is significant.
• Penile or vaginal augmentation — Limited published safety data, no FDA-cleared products for these uses, and complex vascular anatomy.
• Injection of topical-only products (PDGF, exosomes, cosmeceuticals) — When a product formulated and marketed for topical use is injected, the regulatory classification changes entirely. This is unapproved use, not off-label use, and carries both clinical risk and significant legal exposure.

Practical Guidance

For patients

• Ask whether your treatment is on-label or off-label. A good provider will explain this without hesitation.
• Ask about the evidence. "Off-label" does not mean "unstudied." Many off-label uses have substantial published literature behind them.
• Ask about specific risks for the proposed treatment area. The risk profile for filler in the lips is different from filler in the nose or tear troughs — even with the same product.
• Ensure written consent addresses the off-label nature. If the consent form does not mention it, ask why.

For providers

• Document the clinical rationale. Why is this off-label use appropriate for this specific patient? What evidence supports it?
• Maintain current consent forms. Each product and treatment area should have a consent form that specifically addresses the off-label indication, the evidence base, and the area-specific risks.
• Verify malpractice coverage. Confirm with your carrier that off-label aesthetic injections are covered under your policy. Some carriers have begun requesting information about the percentage of off-label treatments performed.
• Stay current on state enforcement trends. 17 states introduced new med spa legislation in 2025, many with specific provisions about informed consent, delegation, and supervision. What was compliant in 2024 may not be compliant today.

The Bottom Line

Off-label use is woven into the fabric of aesthetic medicine. It is how the field evolves, how providers customize treatments, and how patients access techniques that have not yet completed the FDA's indication-specific review process. It is legal, it is common, and in many cases it is the standard of care.

But it is not the same as on-label treatment. The FDA has not reviewed the specific use. The evidence base may be thinner. The risk profile may differ. And the consent obligation is higher.

Both patients and providers benefit from transparency: saying clearly what is on-label, what is off-label, what the evidence supports, and what remains uncertain. That transparency — not the absence of off-label use — is what distinguishes responsible aesthetic practice.

Sources

• U.S. FDA, "Dermal Fillers (Soft Tissue Fillers)." https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers
• ASPS, "FDA-Approved Aesthetic Treatments vs. Off-Label Options." https://www.plasticsurgery.org/news/articles/fda-approved-aesthetic-treatments-vs-off-label-options
• Practical Dermatology, "Legality of PDGF — Off-Label or Out of Bounds?" October 2025. https://practicaldermatology.com/issues/october-2025/legalities-of-injecting-pdgf-off-label-or-out-of-bounds/39754
• Practical Dermatology, "Understanding the Legalities of Off-Label Use." https://practicaldermatology.com/topics/practice-management/understanding-the-legalities-of-off-label-use/20317
• Drug & Device Law Blog, "The January 6, 2025 Final Guidance on Off-Label Use." https://www.druganddevicelawblog.com/2025/01/the-january-6-2025-final-guidance-on-off-label-use.html
• EMMA International, "How the FDA is Regulating Medical Aesthetic Services." https://emmainternational.com/how-the-fda-is-regulating-medical-aesthetic-services
• AAOPM, "Who Can Legally Inject Botox? Understanding Professional Qualifications for Healthcare Providers." https://aaopm.com/blog/who-can-legally-inject-botox-professional-qualifications-healthcare-providers
• Abrams Fensterman, "New York Steps Up Enforcement Against Med Spas." https://www.abramslaw.com/media/announcements/botox-fillers-and-investigations-new-york-steps-up-enforcement-against-med-spas
• OptiMantra, "Rhode Island Passes New Med Spa Law: What You Need to Know for 2025–2026." https://www.optimantra.com/news/rhode-island-passes-new-med-spa-law-what-you-need-to-know-for-2025-2026